Ionis Pharmaceuticals, Inc. (IONS)
USD 27.15
(-4.8%)
USD 27.15
(-4.8%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.6 Billion USD | 32.76% |
| 2022 | 1.96 Billion USD | 6.58% |
| 2021 | 1.84 Billion USD | 18.94% |
| 2020 | 1.54 Billion USD | -0.06% |
| 2019 | 1.54 Billion USD | 4.55% |
| 2018 | 1.48 Billion USD | 63.91% |
| 2017 | 903.3 Million USD | 11.12% |
| 2016 | 812.9 Million USD | 7.62% |
| 2015 | 755.31 Million USD | 8.21% |
| 2014 | 698.02 Million USD | 48.91% |
| 2013 | 468.76 Million USD | 29.17% |
| 2012 | 362.92 Million USD | 15.78% |
| 2011 | 313.46 Million USD | 2.46% |
| 2010 | 305.93 Million USD | -13.85% |
| 2009 | 355.11 Million USD | -24.43% |
| 2008 | 469.9 Million USD | 89.01% |
| 2007 | 248.61 Million USD | 57.35% |
| 2006 | 158 Million USD | -3.48% |
| 2005 | 163.7 Million USD | -41.65% |
| 2004 | 280.55 Million USD | 4.78% |
| 2003 | 267.76 Million USD | -5.45% |
| 2002 | 283.2 Million USD | 46.01% |
| 2001 | 193.96 Million USD | 65.94% |
| 2000 | 116.89 Million USD | 14.26% |
| 1999 | 102.3 Million USD | 1.99% |
| 1998 | 100.3 Million USD | 20.84% |
| 1997 | 83 Million USD | 93.47% |
| 1996 | 42.9 Million USD | 81.01% |
| 1995 | 23.7 Million USD | 15.05% |
| 1994 | 20.6 Million USD | 1.48% |
| 1993 | 20.3 Million USD | 29.3% |
| 1992 | 15.7 Million USD | 8.28% |
| 1991 | 14.5 Million USD | 457.69% |
| 1990 | 2.6 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.42 Billion USD | -1.62% |
| 2024 Q1 | 2.46 Billion USD | -5.22% |
| 2023 Q3 | 2.61 Billion USD | 2.99% |
| 2023 Q2 | 2.54 Billion USD | 6.05% |
| 2023 Q1 | 2.39 Billion USD | 22.28% |
| 2023 FY | 2.6 Billion USD | 32.76% |
| 2023 Q4 | 2.6 Billion USD | -0.6% |
| 2022 Q4 | 1.96 Billion USD | 7.3% |
| 2022 Q3 | 1.82 Billion USD | -0.21% |
| 2022 Q1 | 1.8 Billion USD | -1.66% |
| 2022 FY | 1.96 Billion USD | 6.58% |
| 2022 Q2 | 1.83 Billion USD | 1.21% |
| 2021 FY | 1.84 Billion USD | 18.94% |
| 2021 Q2 | 1.91 Billion USD | 22.09% |
| 2021 Q1 | 1.56 Billion USD | 1.36% |
| 2021 Q4 | 1.84 Billion USD | -2.35% |
| 2021 Q3 | 1.88 Billion USD | -1.57% |
| 2020 FY | 1.54 Billion USD | -0.06% |
| 2020 Q4 | 1.54 Billion USD | 3.87% |
| 2020 Q2 | 1.48 Billion USD | -2.39% |
| 2020 Q1 | 1.52 Billion USD | -1.78% |
| 2020 Q3 | 1.48 Billion USD | 0.35% |
| 2019 Q4 | 1.54 Billion USD | 10.81% |
| 2019 Q1 | 1.44 Billion USD | -2.17% |
| 2019 Q2 | 1.42 Billion USD | -1.9% |
| 2019 FY | 1.54 Billion USD | 4.55% |
| 2019 Q3 | 1.39 Billion USD | -1.69% |
| 2018 Q4 | 1.48 Billion USD | 5.18% |
| 2018 Q3 | 1.4 Billion USD | -1.55% |
| 2018 Q1 | 912.45 Million USD | 1.01% |
| 2018 FY | 1.48 Billion USD | 63.91% |
| 2018 Q2 | 1.42 Billion USD | 56.71% |
| 2017 Q4 | 903.3 Million USD | 5.66% |
| 2017 Q1 | 882.19 Million USD | 8.52% |
| 2017 FY | 903.3 Million USD | 11.12% |
| 2017 Q3 | 854.89 Million USD | -2.33% |
| 2017 Q2 | 875.26 Million USD | -0.79% |
| 2016 FY | 812.9 Million USD | 7.62% |
| 2016 Q1 | 717.65 Million USD | -4.99% |
| 2016 Q2 | 699.89 Million USD | -2.47% |
| 2016 Q3 | 703.94 Million USD | 0.58% |
| 2016 Q4 | 812.9 Million USD | 15.48% |
| 2015 Q3 | 742.59 Million USD | 9.86% |
| 2015 Q1 | 679.58 Million USD | -2.64% |
| 2015 Q4 | 755.31 Million USD | 1.71% |
| 2015 Q2 | 675.93 Million USD | -0.54% |
| 2015 FY | 755.31 Million USD | 8.21% |
| 2014 Q3 | 449.03 Million USD | -0.42% |
| 2014 Q4 | 698.02 Million USD | 55.45% |
| 2014 FY | 698.02 Million USD | 48.91% |
| 2014 Q2 | 450.91 Million USD | -2.08% |
| 2014 Q1 | 460.51 Million USD | -1.76% |
| 2013 Q3 | 480.47 Million USD | 23.97% |
| 2013 Q4 | 468.76 Million USD | -2.44% |
| 2013 Q1 | 351.87 Million USD | -3.04% |
| 2013 FY | 468.76 Million USD | 29.17% |
| 2013 Q2 | 387.57 Million USD | 10.15% |
| 2012 Q3 | 315.4 Million USD | -0.84% |
| 2012 FY | 362.92 Million USD | 15.78% |
| 2012 Q4 | 362.92 Million USD | 15.07% |
| 2012 Q1 | 319.93 Million USD | 2.07% |
| 2012 Q2 | 318.08 Million USD | -0.58% |
| 2011 Q3 | 318.96 Million USD | 0.51% |
| 2011 Q2 | 317.35 Million USD | 14.06% |
| 2011 Q1 | 278.23 Million USD | -9.05% |
| 2011 FY | 313.46 Million USD | 2.46% |
| 2011 Q4 | 313.46 Million USD | -1.72% |
| 2010 Q1 | 315.28 Million USD | -11.22% |
| 2010 FY | 305.93 Million USD | -13.85% |
| 2010 Q4 | 305.93 Million USD | -5.03% |
| 2010 Q2 | 344.12 Million USD | 9.15% |
| 2010 Q3 | 322.14 Million USD | -6.39% |
| 2009 FY | 355.11 Million USD | -24.43% |
| 2009 Q2 | 403.34 Million USD | -4.38% |
| 2009 Q3 | 375.75 Million USD | -6.84% |
| 2009 Q4 | 355.11 Million USD | -5.49% |
| 2009 Q1 | 421.83 Million USD | -10.23% |
| 2008 Q1 | 327.94 Million USD | 31.91% |
| 2008 Q4 | 469.9 Million USD | -1.48% |
| 2008 Q3 | 476.94 Million USD | -6.34% |
| 2008 Q2 | 509.22 Million USD | 55.28% |
| 2008 FY | 469.9 Million USD | 89.01% |
| 2007 FY | 248.61 Million USD | 57.35% |
| 2007 Q1 | 270.47 Million USD | 71.18% |
| 2007 Q2 | 201.04 Million USD | -25.67% |
| 2007 Q3 | 202.81 Million USD | 0.88% |
| 2007 Q4 | 248.61 Million USD | 22.58% |
| 2006 Q2 | 156.45 Million USD | -1.47% |
| 2006 FY | 158 Million USD | -3.48% |
| 2006 Q4 | 158 Million USD | 2.49% |
| 2006 Q3 | 154.17 Million USD | -1.46% |
| 2006 Q1 | 158.78 Million USD | -3.01% |
| 2005 Q1 | 279.79 Million USD | -0.27% |
| 2005 Q3 | 173.34 Million USD | -35.97% |
| 2005 Q4 | 163.7 Million USD | -5.56% |
| 2005 Q2 | 270.71 Million USD | -3.25% |
| 2005 FY | 163.7 Million USD | -41.65% |
| 2004 Q3 | 272.91 Million USD | 1.7% |
| 2004 Q4 | 280.55 Million USD | 2.8% |
| 2004 Q1 | 265.17 Million USD | -0.97% |
| 2004 FY | 280.55 Million USD | 4.78% |
| 2004 Q2 | 268.35 Million USD | 1.2% |
| 2003 Q4 | 267.76 Million USD | 2.97% |
| 2003 FY | 267.76 Million USD | -5.45% |
| 2003 Q3 | 260.03 Million USD | 0.78% |
| 2003 Q2 | 258.02 Million USD | -8.12% |
| 2003 Q1 | 280.82 Million USD | -0.84% |
| 2002 Q2 | 256.85 Million USD | 30.55% |
| 2002 Q4 | 283.2 Million USD | 11.52% |
| 2002 FY | 283.2 Million USD | 46.01% |
| 2002 Q1 | 196.75 Million USD | 1.44% |
| 2002 Q3 | 253.95 Million USD | -1.13% |
| 2001 Q4 | 193.96 Million USD | 9.97% |
| 2001 FY | 193.96 Million USD | 65.94% |
| 2001 Q3 | 176.38 Million USD | 24.56% |
| 2001 Q2 | 141.6 Million USD | 19.1% |
| 2001 Q1 | 118.89 Million USD | 1.72% |
| 2000 Q1 | 103.95 Million USD | 1.62% |
| 2000 FY | 116.89 Million USD | 14.26% |
| 2000 Q2 | 107.26 Million USD | 3.18% |
| 2000 Q3 | 110.61 Million USD | 3.12% |
| 2000 Q4 | 116.89 Million USD | 5.68% |
| 1999 Q3 | 103.4 Million USD | 2.89% |
| 1999 Q2 | 100.5 Million USD | 1.93% |
| 1999 Q4 | 102.3 Million USD | -1.06% |
| 1999 Q1 | 98.6 Million USD | -1.69% |
| 1999 FY | 102.3 Million USD | 1.99% |
| 1998 Q1 | 76.7 Million USD | -7.59% |
| 1998 Q4 | 100.3 Million USD | 5.69% |
| 1998 Q3 | 94.9 Million USD | -9.53% |
| 1998 FY | 100.3 Million USD | 20.84% |
| 1998 Q2 | 104.9 Million USD | 36.77% |
| 1997 Q1 | 46.8 Million USD | 9.09% |
| 1997 Q3 | 55.9 Million USD | -2.1% |
| 1997 FY | 83 Million USD | 93.47% |
| 1997 Q4 | 83 Million USD | 48.48% |
| 1997 Q2 | 57.1 Million USD | 22.01% |
| 1996 Q3 | 24.9 Million USD | -3.49% |
| 1996 Q2 | 25.8 Million USD | -5.15% |
| 1996 FY | 42.9 Million USD | 81.01% |
| 1996 Q1 | 27.2 Million USD | 14.77% |
| 1996 Q4 | 42.9 Million USD | 72.29% |
| 1995 Q4 | 23.7 Million USD | -11.9% |
| 1995 Q2 | 20.3 Million USD | 3.05% |
| 1995 Q3 | 26.9 Million USD | 32.51% |
| 1995 Q1 | 19.7 Million USD | -4.37% |
| 1995 FY | 23.7 Million USD | 15.05% |
| 1994 Q1 | 17.2 Million USD | -15.27% |
| 1994 FY | 20.6 Million USD | 1.48% |
| 1994 Q4 | 20.6 Million USD | 6.19% |
| 1994 Q2 | 16.6 Million USD | -3.49% |
| 1994 Q3 | 19.4 Million USD | 16.87% |
| 1993 Q2 | 14.2 Million USD | -0.7% |
| 1993 FY | 20.3 Million USD | 29.3% |
| 1993 Q3 | 16.7 Million USD | 17.61% |
| 1993 Q4 | 20.3 Million USD | 21.56% |
| 1993 Q1 | 14.3 Million USD | -8.92% |
| 1992 Q2 | 15.1 Million USD | 4.86% |
| 1992 FY | 15.7 Million USD | 8.28% |
| 1992 Q1 | 14.4 Million USD | -0.69% |
| 1992 Q3 | 15.6 Million USD | 3.31% |
| 1992 Q4 | 15.7 Million USD | 0.64% |
| 1991 FY | 14.5 Million USD | 457.69% |
| 1991 Q3 | 9.3 Million USD | -7.92% |
| 1991 Q4 | 14.5 Million USD | 55.91% |
| 1991 Q1 | 6.2 Million USD | 138.46% |
| 1991 Q2 | 10.1 Million USD | 62.9% |
| 1990 Q4 | 2.6 Million USD | 0.0% |
| 1990 FY | 2.6 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | -675.334% |
| Alkermes plc | 933.53 Million USD | -178.873% |
| Agenus Inc. | 462.29 Million USD | -463.144% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 35.727% |
| Aptorum Group Limited | 5.25 Million USD | -49424.743% |
| Ardelyx, Inc. | 130.76 Million USD | -1890.919% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | -444.197% |
| Bicycle Therapeutics plc | 224.41 Million USD | -1060.092% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -1899.375% |
| ChromaDex Corporation | 26.5 Million USD | -9721.133% |
| Chimerix, Inc. | 19.74 Million USD | -13085.039% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -7300.795% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -3487.562% |
| CRISPR Therapeutics AG | 346.76 Million USD | -650.757% |
| Precision BioSciences, Inc. | 140.92 Million USD | -1747.421% |
| Dyadic International, Inc. | 2.34 Million USD | -111124.869% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -15908.03% |
| Fortress Biotech, Inc. | 165.93 Million USD | -1468.881% |
| Lantern Pharma Inc. | 2.73 Million USD | -94925.116% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -3542.118% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -73676.959% |
| Incyte Corporation | 1.59 Billion USD | -63.502% |
| IO Biotech, Inc. | 17.55 Million USD | -14729.039% |
| Jaguar Health, Inc. | 45.86 Million USD | -5576.069% |
| Novavax, Inc. | 2.57 Billion USD | -1.21% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -7119.996% |
| Opthea Limited | 264.6 Million USD | -883.89% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -1891.772% |
| ContextLogic Inc. | 206 Million USD | -1163.78% |
| MiMedx Group, Inc. | 96.33 Million USD | -2602.57% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -5321.236% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -73673.572% |
| NextCure, Inc. | 14.99 Million USD | -17259.379% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -64308.362% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -38890.355% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -5470.051% |
| Vaxcyte, Inc. | 167.44 Million USD | -1454.734% |
| PDS Biotechnology Corporation | 33.25 Million USD | -7727.582% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | -1006.816% |
| Pharming Group N.V. | 244.07 Million USD | -966.642% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -21736.823% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -1937.222% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -39301.787% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -39301.787% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -3058.184% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -39089.914% |
| Acelyrin, Inc. | 86.35 Million USD | -2914.818% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -200277.451% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -18005.473% |
| Summit Therapeutics Inc. | 125.25 Million USD | -1978.436% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -27364.775% |
| Senti Biosciences, Inc. | 52.57 Million USD | -4852.133% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -3685.257% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | -1618.271% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -132997.444% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -194827.836% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | -1047.715% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -27693.168% |
| Wave Life Sciences Ltd. | 227.44 Million USD | -1044.622% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | -426.459% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -23753.638% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -9363.073% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -21407.235% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | -435.015% |
| Immix Biopharma, Inc. | 3.72 Million USD | -69849.968% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -6785.079% |
| MEI Pharma, Inc. | 8.35 Million USD | -31059.617% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -8872.552% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | -649.003% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | -1684.742% |
| Fortress Biotech, Inc. | 165.93 Million USD | -1468.881% |
| Precigen, Inc. | 41.64 Million USD | -6151.527% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -5114.072% |
| AlloVir, Inc. | 45.01 Million USD | -5683.374% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -1897.427% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -1789.25% |
| ImmuCell Corporation | 18.81 Million USD | -13736.74% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -9123.361% |
| Onconetix, Inc. | 23.18 Million USD | -11130.743% |
| PureTech Health plc | 125.58 Million USD | -1973.04% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -28988.112% |
| Elevation Oncology, Inc. | 34.28 Million USD | -7494.032% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -106377.955% |
| Seer, Inc. | 39.36 Million USD | -6513.454% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -4110.282% |
| Innoviva, Inc. | 568.55 Million USD | -357.898% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -9461.429% |
| ESSA Pharma Inc. | 3.49 Million USD | -74387.357% |
| GlycoMimetics, Inc. | 6.9 Million USD | -37618.894% |
| GT Biopharma, Inc. | 6.63 Million USD | -39148.997% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | -884.676% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | -856.118% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -2998.31% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -26535.83% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -9482.193% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -80605.803% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -3429.201% |
| Aptose Biosciences Inc. | 15.8 Million USD | -16368.058% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -23482.066% |
| Soligenix, Inc. | 7.27 Million USD | -35685.847% |
| Century Therapeutics, Inc. | 175.94 Million USD | -1379.693% |
| Kura Oncology, Inc. | 51.66 Million USD | -4939.267% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -2046.556% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -62890.225% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -39262.611% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | -930.644% |
| Autolus Therapeutics plc | 263.9 Million USD | -886.479% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -24736.73% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -2829.728% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -5451.048% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | -637.804% |
| GRI Bio, Inc. | 2.69 Million USD | -96428.958% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -321470.434% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -8273.439% |
| IGM Biosciences, Inc. | 220.17 Million USD | -1082.406% |
| INmune Bio, Inc. | 18.86 Million USD | -13702.28% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -915.048% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -9671.805% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -95668.844% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -79265.088% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -4353.658% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -2607.376% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -883.393% |
| Coherus BioSciences, Inc. | 823.02 Million USD | -216.318% |
| Verastem, Inc. | 71.18 Million USD | -3557.211% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -5194.017% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -6648.37% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -5220.416% |
| Histogen Inc. | 5.69 Million USD | -45597.49% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -59262.072% |
| Surrozen, Inc. | 8.14 Million USD | -31862.996% |
| Organovo Holdings, Inc. | 2.74 Million USD | -94637.482% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -829378.936% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -4529.897% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -15666.63% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -4994.39% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -314746.379% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -1954.359% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -23975.131% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | -1625.365% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -99748.16% |
| Apollomics, Inc. | 14.15 Million USD | -18294.588% |
| Amarin Corporation plc | 279.58 Million USD | -831.154% |
| Mesoblast Limited | 188.79 Million USD | -1278.927% |
| Turnstone Biologics Corp. | 14.14 Million USD | -18301.088% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | -1340.021% |
| Synaptogenix, Inc. | 5.52 Million USD | -46982.025% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -39060.439% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | -1430.431% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -30323.364% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -148039.09% |
| Exelixis, Inc. | 678.44 Million USD | -283.728% |
| Better Therapeutics, Inc. | 23.84 Million USD | -10819.327% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | -1486.985% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | -338.126% |
| NLS Pharmaceutics AG | 10.68 Million USD | -24275.808% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -160244.934% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -6587.867% |
| Gritstone bio, Inc. | 125.91 Million USD | -1967.508% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -17639.071% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -51060.873% |
| Avid Bioservices, Inc. | 275.66 Million USD | -844.392% |
| Insmed Incorporated | 1.66 Billion USD | -56.664% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -33736.468% |
| MediWound Ltd. | 27.18 Million USD | -9475.849% |
| OmniAb, Inc. | 87.4 Million USD | -2878.703% |
| Alector, Inc. | 487.66 Million USD | -433.843% |
| Seres Therapeutics, Inc. | 403.45 Million USD | -545.271% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -14029.639% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -6684.421% |
| Zai Lab Limited | 240.17 Million USD | -983.945% |
| Revance Therapeutics, Inc. | 630.05 Million USD | -313.198% |
| Aura Biosciences, Inc. | 29.22 Million USD | -8807.469% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -2638.187% |
| Immunic, Inc. | 25.36 Million USD | -10162.48% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -3660.162% |
| Veracyte, Inc. | 93.71 Million USD | -2677.864% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -99392.218% |
| FibroGen, Inc. | 585.72 Million USD | -344.47% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -14876.621% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -398534.462% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -45933.159% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 65.997% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -31656.355% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -2998.458% |
| TG Therapeutics, Inc. | 169.08 Million USD | -1439.691% |
| Galecto, Inc. | 5.89 Million USD | -44055.122% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -31326.678% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 0.573% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -8932.635% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -20527.415% |
| XBiotech Inc. | 8.39 Million USD | -30903.763% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -17639.071% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -4795.423% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | -616.977% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -9583.775% |
| Theravance Biopharma, Inc. | 169 Million USD | -1440.429% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | -114.165% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | -420.234% |
| Vaxxinity, Inc. | 30.94 Million USD | -8313.217% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | -167.704% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -43065.973% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | -249.338% |
| NexImmune, Inc. | 5.08 Million USD | -51105.098% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -700876.86% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -84567.145% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 63.369% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -50411.658% |
| Scopus BioPharma Inc. | 7.45 Million USD | -34823.993% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -9801.065% |
| Ainos, Inc. | 7.39 Million USD | -35108.378% |
| Pluri Inc. | 34.11 Million USD | -7531.877% |
| Prothena Corporation plc | 135.01 Million USD | -1828.191% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | -970.898% |
| Celularity Inc. | 102.92 Million USD | -2429.303% |
| Rallybio Corporation | 9.43 Million USD | -27489.932% |
| Cue Biopharma, Inc. | 24.44 Million USD | -10549.973% |
| MeiraGTx Holdings plc | 319.99 Million USD | -713.581% |
| Omeros Corporation | 403.25 Million USD | -545.598% |
| Humacyte, Inc. | 114.67 Million USD | -2170.19% |
| Immunocore Holdings plc | 228.15 Million USD | -1041.045% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -53302.79% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -3292.476% |
| Blueprint Medicines Corporation | 918.64 Million USD | -183.395% |
| CalciMedica, Inc. | 4.02 Million USD | -64532.224% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -14817.408% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | -1588.942% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -2933.648% |
| Sana Biotechnology, Inc. | 277.79 Million USD | -837.168% |
| Pulmatrix, Inc. | 15.96 Million USD | -16208.877% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -16405.332% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -10480.289% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -938.0% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -5026.187% |
| Cytokinetics, Incorporated | 1.21 Billion USD | -115.042% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -8091.127% |
| Nutriband Inc. | 1.07 Million USD | -241195.778% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -24384.021% |
| Vor Biopharma Inc. | 59.1 Million USD | -4304.754% |
| Roivant Sciences Ltd. | 773.95 Million USD | -236.375% |
| Evogene Ltd. | 17.99 Million USD | -14371.295% |
| ProKidney Corp. | 29.21 Million USD | -8810.823% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -3516.869% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -369183.515% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | -37.824% |
| CorMedix Inc. | 11.91 Million USD | -21745.017% |
| BioLineRx Ltd. | 50.7 Million USD | -5034.681% |
| Tango Therapeutics, Inc. | 149.45 Million USD | -1641.873% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -2843.642% |
| Atai Life Sciences N.V. | 49.16 Million USD | -5195.525% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -8256.961% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -14393.854% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -1988.791% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -45945.03% |
| MediciNova, Inc. | 3.89 Million USD | -66798.382% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -14142.497% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -172969.741% |
| GeoVax Labs, Inc. | 3.51 Million USD | -73862.33% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -555.337% |
| Biomea Fusion, Inc. | 30.69 Million USD | -8382.848% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 4.348% |
| Mereo BioPharma Group plc | 15.96 Million USD | -16209.899% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -8243.918% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -4336.279% |
| Absci Corporation | 58.3 Million USD | -4365.193% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -13567.503% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -8019.849% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -3428.101% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -2875.876% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -7609.168% |
| Allakos Inc. | 74.79 Million USD | -3380.788% |
| Imunon, Inc. | 8.53 Million USD | -30418.824% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -11470.09% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -2167.521% |
| BioAtla, Inc. | 48.98 Million USD | -5214.551% |
| NLS Pharmaceutics AG | 10.68 Million USD | -24275.808% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -93580.677% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -1893.343% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -18214.358% |
| XOMA Corporation | 145.58 Million USD | -1688.285% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -7633.213% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -3686.248% |
| aTyr Pharma, Inc. | 31.59 Million USD | -8139.346% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -4111.031% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -5689.805% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -5278.674% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -90610.314% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -31811.991% |
| Akari Therapeutics, Plc | 4.58 Million USD | -56692.888% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -14580.916% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | -57.832% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -644449.254% |
| UroGen Pharma Ltd. | 243.52 Million USD | -969.051% |
| Sutro Biopharma, Inc. | 321.08 Million USD | -710.804% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -94172.364% |
| Orgenesis Inc. | 35.53 Million USD | -7226.259% |
| Entera Bio Ltd. | 1.37 Million USD | -188687.962% |
| GH Research PLC | 6.7 Million USD | -38750.709% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -38185.088% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -13728.673% |
| Xencor, Inc. | 283.55 Million USD | -818.111% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -87095.894% |
| Replimune Group, Inc. | 113.21 Million USD | -2199.527% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -69191.972% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -2414.62% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -644449.254% |
| Portage Biotech Inc. | 4.45 Million USD | -58403.056% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -172969.741% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -11194.516% |
| OncoCyte Corporation | 49.29 Million USD | -5180.916% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -62832.287% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -326349.935% |
| Purple Biotech Ltd. | 10 Million USD | -25920.85% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -44894.573% |
| scPharmaceuticals Inc. | 57.26 Million USD | -4446.526% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -20915.35% |
| HilleVax, Inc. | 78.9 Million USD | -3199.226% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -51452.198% |
| Tharimmune, Inc. | 1.81 Million USD | -143333.61% |
| Genprex, Inc. | 3.25 Million USD | -79900.602% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -9499.86% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -49620.894% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -1263679.612% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -725991.346% |
| OKYO Pharma Limited | 7.42 Million USD | -34982.065% |
| Savara Inc. | 37.19 Million USD | -6899.855% |
| Curis, Inc. | 57.61 Million USD | -4418.826% |
| Daré Bioscience, Inc. | 26.32 Million USD | -9787.582% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -6541.326% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -180189.889% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -12404.856% |
| BeiGene, Ltd. | 2.23 Billion USD | -16.548% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -12128.325% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | -892.155% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -12137.407% |
| Erasca, Inc. | 78.61 Million USD | -3211.732% |
| bluebird bio, Inc. | 424.62 Million USD | -513.104% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -397210.653% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | -37.741% |
| DBV Technologies S.A. | 42.8 Million USD | -5982.678% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -397210.653% |
| Moderna, Inc. | 4.57 Billion USD | 43.058% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -37117.813% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -157109.3% |
| Molecular Templates, Inc. | 31.17 Million USD | -8251.949% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -15151.236% |
| Travere Therapeutics, Inc. | 588.1 Million USD | -342.675% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -1990.989% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -9388.596% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -7041.173% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -4579.403% |
| MacroGenics, Inc. | 154.2 Million USD | -1588.241% |
| RenovoRx, Inc. | 4.46 Million USD | -58193.462% |
| Adicet Bio, Inc. | 37.12 Million USD | -6913.432% |
| Prime Medicine, Inc. | 60.78 Million USD | -4183.294% |
| Aditxt, Inc. | 28.53 Million USD | -9024.584% |
| Adagene Inc. | 45.16 Million USD | -5663.613% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -1440614.772% |
| Quantum-Si incorporated | 26.63 Million USD | -9675.773% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | -273.21% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -85469.073% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -2164.582% |
| SciSparc Ltd. | 1.59 Million USD | -163121.693% |
| Vericel Corporation | 127.7 Million USD | -1938.594% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -46682.311% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -2949.958% |
| Generation Bio Co. | 171.63 Million USD | -1416.86% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -22440.139% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -6123.581% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | -930.236% |
| Invivyd, Inc. | 51.71 Million USD | -4934.297% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -2730.475% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -39919.762% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -3348.376% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -254883.937% |
| 2seventy bio, Inc. | 310.12 Million USD | -739.461% |
| ADMA Biologics, Inc. | 193.97 Million USD | -1242.118% |
| Clene Inc. | 38.95 Million USD | -6583.746% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -7105.037% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | -913.085% |
| GeoVax Labs, Inc. | 3.51 Million USD | -73862.33% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | -1268.309% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -21274.862% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | -1212.707% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -21248.329% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -5311.207% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -4826.83% |
| Vir Biotechnology, Inc. | 369.85 Million USD | -603.896% |
| Evaxion Biotech A/S | 17.61 Million USD | -14677.289% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | -1517.723% |
| Verve Therapeutics, Inc. | 153.18 Million USD | -1599.493% |
| Trevena, Inc. | 48.26 Million USD | -5294.277% |
| Surrozen, Inc. | 8.14 Million USD | -31862.996% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -11955.504% |
| Cingulate Inc. | 10.36 Million USD | -25027.111% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -94568.582% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -6881.084% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -72488.08% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -19697.612% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | -720.737% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -10376.824% |
| Clearmind Medicine Inc. | 3.61 Million USD | -72015.796% |
| Kronos Bio, Inc. | 54.2 Million USD | -4703.207% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -5434.056% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -11338.562% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -12870.883% |
| Statera Biopharma, Inc. | 22.67 Million USD | -11380.57% |
| ImmunityBio, Inc. | 1.09 Billion USD | -138.758% |
| Korro Bio, Inc. | 51.75 Million USD | -4930.503% |
| Kineta, Inc. | 7.22 Million USD | -35947.992% |
| BioVie Inc. | 9.7 Million USD | -26733.139% |
| Codexis, Inc. | 49.94 Million USD | -5112.401% |
| Celularity Inc. | 102.92 Million USD | -2429.303% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -2604.901% |
| Celcuity Inc. | 51.45 Million USD | -4960.024% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -754080.548% |
| Cibus, Inc. | 206.11 Million USD | -1163.062% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -6029.22% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -9784.149% |
| IN8bio, Inc. | 8.77 Million USD | -29578.363% |
| Kodiak Sciences Inc. | 213.59 Million USD | -1118.865% |
| Annexon, Inc. | 47.11 Million USD | -5425.247% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -2807.479% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -2601.393% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -18918.088% |
| Eyenovia, Inc. | 19.78 Million USD | -13061.522% |
| Puma Biotechnology, Inc. | 177.08 Million USD | -1370.125% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -33793.842% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -10702.88% |
| Arcellx, Inc. | 339.75 Million USD | -666.261% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -21780.871% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | -960.27% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -27123.528% |
| Moolec Science SA | 13.94 Million USD | -18568.48% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -5933.06% |
| Geron Corporation | 146.12 Million USD | -1681.591% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -5051.955% |
| Royalty Pharma plc | 6.29 Billion USD | 58.66% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -6445.118% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -884184.288% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -105716.569% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | -1276.317% |
| Humacyte, Inc. | 114.67 Million USD | -2170.19% |
| Structure Therapeutics Inc. | 29.05 Million USD | -8861.432% |
| 89bio, Inc. | 59.96 Million USD | -4241.654% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -9737.834% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -217574.415% |
| Genelux Corporation | 8.42 Million USD | -30819.074% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -37872.375% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -1809.775% |
| Notable Labs, Ltd. | 4.42 Million USD | -58707.002% |
| Liquidia Corporation | 73.13 Million USD | -3459.553% |
| Mustang Bio, Inc. | 17.61 Million USD | -14676.015% |
| Immunovant, Inc. | 48.95 Million USD | -5217.916% |
| Quantum-Si incorporated | 26.63 Million USD | -9675.773% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -6682.654% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -83799.001% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -3424.71% |
| Acasti Pharma Inc. | 11.55 Million USD | -22426.486% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -11415.468% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -95668.844% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -6959.647% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -190926.252% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -42606.463% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -10382.73% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -11129.236% |
| PepGen Inc. | 34.63 Million USD | -7417.502% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -21337.632% |
| United Therapeutics Corporation | 1.18 Billion USD | -120.215% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -37176.432% |
| Solid Biosciences Inc. | 38.45 Million USD | -6669.426% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -30323.364% |
| Immuneering Corporation | 12 Million USD | -21579.789% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -829378.936% |
| Silo Pharma, Inc. | 1.56 Million USD | -165797.902% |
| Belite Bio, Inc | 4.21 Million USD | -61723.462% |
| XOMA Corporation | 145.58 Million USD | -1688.285% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -107123.476% |
| Bionomics Limited | 10.15 Million USD | -25527.104% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -12013.843% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -11262.048% |
| uniQure N.V. | 624.01 Million USD | -317.197% |
| Cassava Sciences, Inc. | 14.19 Million USD | -18240.162% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -1440614.772% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | -1429.748% |
| Forte Biosciences, Inc. | 3.66 Million USD | -70914.348% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -998962.103% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -38485.831% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -33793.842% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -14876.621% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -24534.614% |
| Altimmune, Inc. | 16.54 Million USD | -15638.988% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -321.46% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -11262.048% |
| Compugen Ltd. | 55.77 Million USD | -4567.658% |
| Peak Bio, Inc. | 20.75 Million USD | -12444.405% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -2256.795% |
| Benitec Biopharma Inc. | 4.96 Million USD | -52366.465% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | -1549.352% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -3363.147% |
| Zura Bio Limited | 21.29 Million USD | -12127.062% |
| PolyPid Ltd. | 17.46 Million USD | -14803.744% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -2216.2% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -3363.147% |
| Instil Bio, Inc. | 99.8 Million USD | -2508.577% |
| argenx SE | 444.95 Million USD | -485.095% |
| Immunome, Inc. | 28.65 Million USD | -8984.325% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -31126.892% |
| Verona Pharma plc | 58.84 Million USD | -4324.442% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -17887.881% |
| Shattuck Labs, Inc. | 14.85 Million USD | -17420.6% |
| CervoMed Inc. | 2.59 Million USD | -100194.289% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -53313.746% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -20341.159% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -24611.78% |
| Moolec Science SA | 13.94 Million USD | -18568.48% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -110989.463% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -4582.745% |
| AnaptysBio, Inc. | 364.28 Million USD | -614.654% |
| Design Therapeutics, Inc. | 11.95 Million USD | -21674.724% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -20424.961% |
| NeurAxis, Inc. | 1.91 Million USD | -136007.749% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -6587.695% |
| Lumos Pharma, Inc. | 13.33 Million USD | -19425.883% |
| Achilles Therapeutics plc | 19.08 Million USD | -13539.577% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -17887.881% |
| 180 Life Sciences Corp. | 5.38 Million USD | -48225.32% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -10936.913% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -11338.562% |
| Nutriband Inc. | 1.07 Million USD | -241195.778% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -8408.353% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -17840.776% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | -548.78% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -7917.079% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -19850.7% |
| Palisade Bio, Inc. | 2.73 Million USD | -94948.777% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -49459.985% |
| Beam Therapeutics Inc. | 478.38 Million USD | -444.203% |
| Neurogene Inc. | 36.54 Million USD | -7023.002% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | -554.198% |
| AEON Biopharma, Inc. | 159.88 Million USD | -1528.246% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -5363.559% |
| Sesen Bio, Inc. | 30.98 Million USD | -8302.356% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -9928.065% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -34145.094% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -1230.036% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | -1255.528% |
| Athira Pharma, Inc. | 30.05 Million USD | -8561.496% |
| Vaccinex, Inc. | 5.94 Million USD | -43713.295% |
| HCW Biologics Inc. | 15.05 Million USD | -17196.013% |
| XOMA Corporation | 145.58 Million USD | -1688.285% |
| Nektar Therapeutics | 267.04 Million USD | -874.883% |
| Arvinas, Inc. | 644.6 Million USD | -303.876% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -14580.916% |
| Merus N.V. | 102.15 Million USD | -2448.566% |
| Omega Therapeutics, Inc. | 146.35 Million USD | -1678.877% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -2636.949% |
| Rezolute, Inc. | 11.73 Million USD | -22086.688% |
| Clene Inc. | 38.95 Million USD | -6583.746% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -91330.929% |
| BeyondSpring Inc. | 48.26 Million USD | -5293.495% |
| Synlogic, Inc. | 32.89 Million USD | -7814.23% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -17715.548% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -159225.949% |
| Peak Bio, Inc. | 20.75 Million USD | -12444.405% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -4002.469% |
| Krystal Biotech, Inc. | 39.71 Million USD | -6455.336% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | -591.206% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -2514.655% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -601524.585% |
| MannKind Corporation | 721.36 Million USD | -260.897% |
| Ikena Oncology, Inc. | 22.33 Million USD | -11556.082% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -124702.78% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -2437.661% |
| Gossamer Bio, Inc. | 249.14 Million USD | -944.92% |
| CohBar, Inc. | 1.03 Million USD | -251766.321% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -24255.749% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -13567.503% |
| Legend Biotech Corporation | 589.93 Million USD | -341.302% |
| Mural Oncology plc | 37.92 Million USD | -6764.021% |
| Biora Therapeutics, Inc. | 132.63 Million USD | -1862.805% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -113320.891% |
| Disc Medicine, Inc. | 22.87 Million USD | -11280.922% |
| Champions Oncology, Inc. | 28.03 Million USD | -9186.199% |
| REGENXBIO Inc. | 262.22 Million USD | -892.795% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -77396.672% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -20670.592% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -19282.507% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -12177.227% |
| Vaxart, Inc. | 34.02 Million USD | -7551.392% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -12668.416% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -9024.481% |
| Cellectis S.A. | 249.57 Million USD | -943.128% |
| Longeveron Inc. | 5.33 Million USD | -48679.951% |
| Repare Therapeutics Inc. | 41.81 Million USD | -6125.366% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | -8.238% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -4212.527% |
| Revolution Medicines, Inc. | 262.39 Million USD | -892.155% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -123458.899% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -30080.686% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -21960.724% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -18438.674% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -120931.427% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 49.447% |
| Denali Therapeutics Inc. | 122.96 Million USD | -2017.211% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -46682.311% |
| Veru Inc. | 32.81 Million USD | -7834.079% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -37800.51% |
| Cingulate Inc. | 10.36 Million USD | -25027.111% |
| Passage Bio, Inc. | 39.26 Million USD | -6530.803% |
| Context Therapeutics Inc. | 4.19 Million USD | -62007.896% |
| Exicure, Inc. | 8.54 Million USD | -30352.521% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -8722.645% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -24727.255% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -11711.56% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | -1497.307% |
| Nuvalent, Inc. | 31.82 Million USD | -8080.831% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -40823.273% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -4030.916% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -14363.256% |
| OmniAb, Inc. | 87.4 Million USD | -2878.703% |
| Anew Medical, Inc. | 8.24 Million USD | -31487.594% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -6699.289% |
| Lipocine Inc. | 2.63 Million USD | -98826.786% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -9809.356% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -6374.152% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -9671.805% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -2921.782% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -48101.926% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -3046.2% |
| Ocugen, Inc. | 23.98 Million USD | -10755.131% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -5509.899% |
| Q32 Bio Inc. | 233.12 Million USD | -1016.72% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -28615.928% |
| Alumis Inc. Common Stock | 53.5 Million USD | -4765.96% |
| Equillium, Inc. | 27.95 Million USD | -9212.108% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | -1160.158% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -46168.722% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -42349.039% |
| Galera Therapeutics, Inc. | 157.32 Million USD | -1554.772% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -3649.494% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -26001.198% |
| Dominari Holdings Inc. | 4.63 Million USD | -56067.983% |
| Edesa Biotech, Inc. | 1.84 Million USD | -141262.603% |
| vTv Therapeutics Inc. | 29.56 Million USD | -8705.039% |
| Bio-Techne Corporation | 744.34 Million USD | -249.758% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -1964.557% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | -655.796% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -6316.232% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -8890.524% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -2718.738% |
| Nkarta, Inc. | 105.6 Million USD | -2365.328% |
| BioCardia, Inc. | 4.59 Million USD | -56618.649% |
| Iterum Therapeutics plc | 32.66 Million USD | -7870.688% |